Results 41 to 50 of about 8,517,970 (127)

Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess. [PDF]

Transl Gastroenterol Hepatol
Given the increasing use of targeted therapies in clinical practice, we aimed to determine the clinically actionable safety profiles of second-line tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (HCC) by analysing adverse drug reactions (ADRs) reported in the WHO-VigiAccess database.Retrospective descriptive analysis of ADR ...
Sui W, Duan Y, Cai Z, Xia Y, Li J, Fu J.
europepmc   +3 more sources

The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency

European Journal of Neurology, Volume 28, Issue 9, Page 2965-2970, September 2021., 2021
From counts of adverse drug reaction reports from databases, the reporting odds ratio can be calculated and serve as a surrogate for the risk of myasthenia worsening due to drugs commonly used in cardiovascular diseases. An increased risk of beta‐blockers and calcium antagonists is confirmed with this method.
Peter Trillenberg, Alexander Katalinic, Julia Thern, Tobias Graf   +3 more
wiley   +1 more source

Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency

European Journal of Neurology, Volume 28, Issue 7, Page 2349-2356, July 2021., 2021
Entries in databases of adverse drug reactions can be used to compare the risk of myasthenia worsening due to drugs. We determined a quantitative surrogate (reporting odds ratio [ROR]) for antiepileptic, antidepressant, neuroleptic, and sedative drugs. Although the ROR was increased for some drugs, their ROR was always smaller than for atorvastatin, a ...
Peter Trillenberg, Alexander Katalinic, Klaus Junghanns, Julia Thern   +3 more
wiley   +1 more source

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Case Reports in Nephrology, 2020
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the
Gisela Marcelino, Ould Maouloud Hemett, Eric Descombes   +2 more
doaj   +1 more source

Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess. [PDF]

Front Oncol
BackgroundCetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is widely used in metastatic colorectal cancer and other solid tumors. Cutaneous adverse events (AEs) are among its most frequent toxicities, but real-
Li C, Gao Y, Guang M, Wu H, Li Y, Lu Y, Wei Y, Li X, Yang L.   +8 more
europepmc   +2 more sources

Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research

, 2023
The Journal of Clinical Pharmacology, Volume 63, Issue 5, Page 521-525, May 2023.
Renato Ferreira da Silva, Ana Marta Silva, Manuela Morato, Inês Ribeiro‐Vaz, Jorge Junqueira Polónia   +4 more
wiley   +1 more source

Common osteoporosis drug associated with increased rates of depression and anxiety

Scientific Reports, 2021
Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease.
Dro Keshishi, Tigran Makunts, Ruben Abagyan   +2 more
doaj   +1 more source

Table1_Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.XLSX

, 2023
Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s ...
Ruxu You, Hongbo Zhou (117916), Hongbo Zhou, Mingming Li (502877), Yuyong Su (16638279), Mingming Li, Yuyong Su, Shiwei Gong, Ruxu You (2558287), Shiwei Gong (702502)   +9 more
core   +1 more source

5种类风湿生物药PT .xlsx

, 2022
adverse events after the use of TNFɑ inhibitors in ...
Li (14126481)
core   +1 more source

Increased Libido Following Brivaracetam Initiation: A Case Report of Temporal Lobe Epilepsy

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
This case report highlights a patient with temporal lobe epilepsy who experienced a distressing libido increase following brivaracetam initiation. Although primarily associated with brivaracetam, incomplete Klüver–Bucy syndrome and concurrent brexpiprazole may have also been involved.
Toru Horinouchi, Taiki Matsuyama, Mayusa Mito, Yuichi Nakamura, Takahiro A. Kato   +4 more
wiley   +1 more source